London
· Delayed Price · Currency is GBP · Price in EUR Pharming Group Statistics
Total Valuation
Pharming Group has a market cap or net worth of GBP 498.24 million. The enterprise value is 464.36 million.
| Market Cap | 498.24M |
| Enterprise Value | 464.36M |
Important Dates
The next estimated earnings date is Friday, April 4, 2025.
| Earnings Date | Apr 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -1.41% |
| Shares Change (QoQ) | -24.96% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 656.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 4.21 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -34.92 |
| EV / Sales | 2.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1,213.23 |
Financial Position
The company has a current ratio of 3.53, with a Debt / Equity ratio of 0.56.
| Current Ratio | 3.53 |
| Quick Ratio | 2.76 |
| Debt / Equity | 0.56 |
| Debt / EBITDA | 209.36 |
| Debt / FCF | -247.73 |
| Interest Coverage | -1.08 |
Financial Efficiency
Return on equity (ROE) is -8.18% and return on invested capital (ROIC) is -1.64%.
| Return on Equity (ROE) | -8.18% |
| Return on Assets (ROA) | -1.38% |
| Return on Capital (ROIC) | -1.64% |
| Revenue Per Employee | 558,100 |
| Profits Per Employee | -34,811 |
| Employee Count | 382 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 0.52 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.19% in the last 52 weeks. The beta is 0.81, so Pharming Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.81 |
| 52-Week Price Change | -21.19% |
| 50-Day Moving Average | 0.82 |
| 200-Day Moving Average | 0.79 |
| Relative Strength Index (RSI) | 48.39 |
| Average Volume (20 Days) | 109,292 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharming Group had revenue of GBP 213.19 million and -13.30 million in losses. Loss per share was -0.02.
| Revenue | 213.19M |
| Gross Profit | 190.58M |
| Operating Income | -7.10M |
| Pretax Income | -12.83M |
| Net Income | -13.30M |
| EBITDA | -2.28M |
| EBIT | -7.10M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 128.15 million in cash and 94.82 million in debt, giving a net cash position of 33.34 million.
| Cash & Cash Equivalents | 128.15M |
| Total Debt | 94.82M |
| Net Cash | 33.34M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 168.46M |
| Book Value Per Share | 0.33 |
| Working Capital | 150.98M |
Cash Flow
In the last 12 months, operating cash flow was 336,491 and capital expenditures -719,240, giving a free cash flow of -382,749.
| Operating Cash Flow | 336,491 |
| Capital Expenditures | -719,240 |
| Free Cash Flow | -382,749 |
| FCF Per Share | n/a |
Margins
Gross margin is 89.39%, with operating and profit margins of -3.33% and -6.24%.
| Gross Margin | 89.39% |
| Operating Margin | -3.33% |
| Pretax Margin | -6.02% |
| Profit Margin | -6.24% |
| EBITDA Margin | -1.07% |
| EBIT Margin | -3.33% |
| FCF Margin | n/a |
Dividends & Yields
Pharming Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.41% |
| Shareholder Yield | 1.41% |
| Earnings Yield | -2.67% |
| FCF Yield | -0.08% |
Stock Splits
The last stock split was on March 5, 2013. It was a reverse split with a ratio of 0.1.
| Last Split Date | Mar 5, 2013 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Pharming Group has an Altman Z-Score of 2.32. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.32 |
| Piotroski F-Score | n/a |